BNP Paribas Financial Markets
QNCX icon

BNP Paribas Financial Markets’s Quince Therapeutics QNCX Stock Holding History

BNP Paribas Financial Markets’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Hold
0
– -$1 – 6107
2026
Q1 		– Hold
0
– – – 5801
2025
Q4 		– Hold
0
– – – 5661
2025
Q3 		– Hold
0
– – – 5514
2025
Q2 		– Hold
0
– – – 5403
2024
Q3 		– Hold
0
– -$18 – 4221
2024
Q2 		– Hold
0
– – – 4010
2024
Q1 		– Hold
0
– – – 3997
2023
Q4 		– Hold
0
– – – 3977
2023
Q3 		– Hold
0
– – – 3863
2023
Q2 		– Sell
-3
Closed -$934 – 3862
2023
Q1 		$1.01K Sell
3
-3
-50% -$587 ﹤0.01% 3686
2022
Q4 		$771 Sell
6
-1,030
-99% -$172K ﹤0.01% 3834
2022
Q3 		$276K Sell
1,036
-392
-27% -$149K ﹤0.01% 3336
2022
Q2 		$634K Sell
1,428
-216
-13% -$153K ﹤0.01% 2523
2022
Q1 		$2.04M Buy
1,644
+746
+83% +$1.02M ﹤0.01% 1798
2021
Q4 		$2.27M Buy
898
+880
+4,889% +$5.37M ﹤0.01% 1915
2021
Q3 		$329K Buy
18
+14
+350% +$223K ﹤0.01% 2901
2021
Q2 		$39.1K Sell
4
-12
-75% -$101K ﹤0.01% 3353
2021
Q1 		$114K Sell
16
-19
-54% -$137K ﹤0.01% 3296
2020
Q4 		$194K Buy
35
+16
+84% +$142K ﹤0.01% 2898
2020
Q3 		$187K Buy
19
+16
+533% +$146K ﹤0.01% 2790
2020
Q2 		$31.4K Sell
3
-14
-82% -$128K ﹤0.01% 3220
2020
Q1 		$158K Buy
17
+9
+113% +$88.8K ﹤0.01% 2972
2019
Q4 		$87.1K Buy
8
+6
+300% +$36.2K ﹤0.01% 3353
2019
Q3 		$9.1K Buy
+2
New +$12.3K ﹤0.01% 4169
2019
Q2 		– Hold
0
– – – 4394

Other funds holding QNCX

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
GWP
Gen-Wealth Partners Zeeland, Michigan $360M AUM 27.44% 1-Year Est. Return
OA
Operose Advisors Milwaukee, Wisconsin $517M AUM 24.68% 1-Year Est. Return
FFO
Fortitude Family Office Scottsdale, Arizona $516M AUM 28.38% 1-Year Est. Return
IWC
Integrated Wealth Concepts Waltham, Massachusetts $20.5B AUM 24.45% 1-Year Est. Return

BNP Paribas Financial Markets's QNCX Position: Q2 2026 in Review

BNP Paribas Financial Markets held its Quince Therapeutics (QNCX) position steady in Q2 2026 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #6107.

BNP Paribas Financial Markets first reported a position in QNCX in Q3 2019 and has held it in 15 quarters since. The position peaked at $2.27M in Q4 2021. 16 funds tracked by Wall St. Rank hold QNCX as of Q2 2026.

  • BNP Paribas Financial Markets held 0 shares of Quince Therapeutics worth $0 as of Q2 2026.
  • BNP Paribas Financial Markets left its Quince Therapeutics share count unchanged in Q2 2026.
  • Quince Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #6107 holding.
  • BNP Paribas Financial Markets first reported a position in Quince Therapeutics in Q3 2019 and has held it in 15 quarters since.
  • BNP Paribas Financial Markets's Quince Therapeutics position peaked at $2.27M in Q4 2021.
  • 16 funds tracked by Wall St. Rank held Quince Therapeutics as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.